logo

For the Inventor, By the Inventor

Tokyo, Japan

Otsuka Pharmaceutical Company, Limited

Calculating rank
USPTO Granted Patents = 846

% Expired Patents = 27.5



Trademarks = 110

Forward Citations = 6,997

Loading Chart...
Loading Chart...

1,282 inventors (with patents filed for the assignee):

goldMedal Michiaki Tominaga (79 out of 80 patents)

silverMedal Kazuyuki Nakagawa (67 out of 67 patents)

bronzeMedal Hiroshi Yamashita (34 out of 93 patents)

4.  Hidenori Ogawa (30 out of 30 patents)

5.  Yoichi Yabuuchi (29 out of 29 patents)

6.  Nobuaki Ito (27 out of 27 patents)

7.  Kazumi Kondo (27 out of 27 patents)

8.  Satoru Nakai (27 out of 27 patents)

9.  Takakuni Matsuda (25 out of 26 patents)

10.  Hisashi Miyamoto (25 out of 25 patents)

11.  Tetsuro Kikuchi (24 out of 25 patents)

12.  Takao Nishi (24 out of 25 patents)

13.  Takafumi Fujioka (24 out of 24 patents)

14.  Shin Miyamura (20 out of 20 patents)

15.  Naoto Utsumi (20 out of 21 patents)


Core Competencies:
Pharmaceutical Formulations
Epilepsy Treatments
Antitumor Compositions
Wearable Sensors
Ingestible Devices
SHP2 Inhibitors
Sleep Improving Agents
Detection Devices
Heterocyclic Compounds
Customized Therapeutic Regimens
Drug Delivery Systems
Medical Devices

846 patents:

1. 12491148 - Adenosine phosphate-containing O/W type emulsion composition having low viscosity (2025-12-09),
2. 12458640 - Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors (2025-11-04),
3. 12391674 - Heterocyclic compounds for the treatment of epilepsy (2025-08-19),
4. 12383181 - Elastic wearable sensor (2025-08-12),
5. 12370144 - Centanafadine pharmaceutical formulations, and methods of making and using same (2025-07-29),
6. 12365950 - Method of detecting conjunctival disease using ocular surface tissue, and aging biomarker (2025-07-22),
7. 12306106 - Detection device (2025-05-20),
8. 12274562 - Re-wearable physiological monitoring device (2025-04-14),
9. 12220410 - Antitumor composition (2025-02-11),
10. 12196674 - Detection device and detection method (2025-01-14),
11. 12195496 - 2'-deoxy-2′,2′-difluorotetrahydrouridines with high purity and methods of making the same (2025-01-14),
12. 12187757 - 2'-deoxy-2′,2′-difluorotetrahydrouridines with high purity and methods of making the same (2025-01-07),
13. 12186312 - Sleep improving agent (2025-01-07),
14. 12156941 - Centanafadine pharmaceutical formulations, and methods of making and using same (2024-12-03),
15. 12152232 - strain (2024-11-26),
Company Overview
Otsuka Pharmaceutical Company, Limited, headquartered in Tokyo, Japan, specializes in the development and manufacturing of innovative pharmaceutical formulations. The company focuses on a diverse range of therapeutic areas, including epilepsy treatments, antitumor compositions, and sleep improving agents. Otsuka is also advancing technologies in wearable sensors and ingestible devices, alongside research into SHP2 inhibitors and detection devices, positioning itself as a leader in the pharmaceutical industry with a commitment to improving patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Otsuka Pharmaceutical Company, Limited USPTO Patent Assignee Logo
846 Patents

#125 in Tokyo

#255 in Japan

#1,194 in the World

Tokyo, JP
Tokyo, Japan

Otsuka Pharmaceutical Company, Limited

Forward Citations = 6,997

1,282 inventors:

goldMedal Michiaki Tominaga (79 out of 80 patents)

silverMedal Kazuyuki Nakagawa (67 out of 67 patents)

bronzeMedal Hiroshi Yamashita (34 out of 93 patents)

4.  Hidenori Ogawa (30 out of 30 patents)

5.  Yoichi Yabuuchi (29 out of 29 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Otsuka Pharmaceutical Company, Limited. Retrieved from https://idiyas.com/company/otsuka-pharmaceutical-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…